{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:47:42Z","timestamp":1790682462417,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ajo.2022.01.015","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T09:41:26Z","timestamp":1642930886000},"page":"11-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1705-7284","authenticated-orcid":false,"given":"Mo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-1678","authenticated-orcid":false,"given":"Yiqun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-6956","authenticated-orcid":false,"given":"Honglu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-3554","authenticated-orcid":false,"given":"Mengying","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-6110","authenticated-orcid":false,"given":"Hongen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-4035","authenticated-orcid":false,"given":"Lindan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-9945","authenticated-orcid":false,"given":"Yongping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-5227","authenticated-orcid":false,"given":"Jost B.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2022.01.015_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ajo.2022.01.015_bib0002","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ajo.2022.01.015_bib0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/WNO.0000000000000779","article-title":"Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome?","volume":"39","author":"Chen","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0004","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"826","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2022.01.015_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"9","key":"10.1016\/j.ajo.2022.01.015_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/jnnp-2019-320493","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up","volume":"90","author":"Petzold","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ajo.2022.01.015_bib0007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"131","author":"Pache","year":"2016","journal-title":"J Neuroinflamm"},{"issue":"10","key":"10.1016\/j.ajo.2022.01.015_bib0008","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2022.01.015_bib0009","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2022.01.015_bib0010","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.ajo.2022.01.015_bib0011","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.01.015_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0013","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2022.01.015_bib0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11910-019-1014-z","article-title":"clinical characteristics and treatment of MOG-IgG-associated optic neuritis","volume":"19","author":"Tajfirouz","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.ajo.2022.01.015_bib0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ajo.2022.01.015_bib0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0017","article-title":"Incidence of multiple sclerosis in China: A nationwide hospital-based study","volume":"1","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ajo.2022.01.015_bib0018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2017.07.013","article-title":"Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: a comparison between Thai and American-Caucasian cohorts","volume":"17","author":"Vanikieti","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2022.01.015_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.ajo.2022.01.015_bib0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2022.01.015_bib0021","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/bjophthalmol-2017-310157","article-title":"Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients","volume":"101","author":"Zhou","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.01.015_bib0022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10792-017-0491-9","article-title":"Clinical characteristics of optic neuritis in Hong Kong population: 10-year review","volume":"38","author":"Choy","year":"2018","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2022.01.015_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4339","article-title":"Association of individual-level factors with visual outcomes in optic neuritis: secondary analysis of a randomized clinical trial","volume":"3","author":"De Lott","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4S","key":"10.1016\/j.ajo.2022.01.015_bib0024","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1016\/j.ophtha.2020.01.027","article-title":"Optic Neuritis Study G. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial","volume":"127","author":"Beck","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2022.01.015_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4015075","article-title":"Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China","volume":"2019","author":"Song","year":"2019","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0027","article-title":"Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study","author":"Xie","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.01.015_bib0028","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bjophthalmol-2018-313142","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy","volume":"103","author":"Liu","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.01.015_bib0029","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","article-title":"Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study","volume":"106","author":"Yang","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0031","article-title":"Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders","author":"Masuda","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0032","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.ajo.2022.01.015_bib0033","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.ajo.2022.01.015_bib0034","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ajo.2022.01.015_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102542","article-title":"Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience","volume":"46","author":"Huang","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2022.01.015_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.737564","article-title":"Physical, emotional, medical, and socioeconomic status of patients with NMOSD: a cross-sectional survey of 123 cases from a single center in North China","volume":"12","author":"Jia","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ajo.2022.01.015_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.602193","article-title":"Low contrast visual acuity might help to detect previous optic neuritis","volume":"11","author":"Park","year":"2020","journal-title":"Front Neurol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:48:15Z","timestamp":1757598495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"alternative-id":["S0002939422000162"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.01.015","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}